Brexanolone: a new drug for postpartum depression
10.3760/cma.j.issn.1008-6706.2019.24.034
- VernacularTitle: 别孕烯醇酮－治疗产后抑郁的新药
- Author:
Jingui ZHANG
1
;
Chao WANG
;
Peiling WAN
;
Yuting YANG
Author Information
1. Department of Pharmacy, the People's Hospital of Hainan, Haikou, Hainan 570311, China
- Publication Type:Journal Article
- Keywords:
Depression, postpartum;
Progesterone;
Antidepressive agents;
Pharmacological action;
Brexanolone
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(24):3070-3072
- CountryChina
- Language:Chinese
-
Abstract:
Brexanolone, also known as 3a, 5a-tetrahydroprogesterone, is a metabolite of progesterone and an important neuroactive steroid with a wide range of biological activities.Recently, the most exciting thing is that 2019 year the FDA has approved its treatment of postpartum depression, which is also the only drug to obtain indications for postpartum depression.It is expected to officially enter the market by the end of June 2019 year.This article reviews the research progress of its pharmacological action.
